Larimar Therapeutics Inc Dossier - Source-backed chat

Larimar Therapeutics Inc

LRMRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.80

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.06Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $317.9M

Enterprise Value $229M

Shares Outstanding 103.9M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Larimar Therapeutics is a high-conviction, clinical-stage biotechnology company uniquely positioned to address the root cause of Friedreich's ataxia (FA) through its lead asset, nomlabofusp (CTI-1601). Unlike existing symptomatic treatments, nomlabofusp is a first-in-class frataxin (FXN) protein replacement therapy designed to deliver mature human FXN directly to the mitochondria. Backed by the FDA's Breakthrough Therapy Designation and participation in the elite START pilot program, Larimar has established a clear, de-risked regulatory pathway. The FDA has aligned on using skin FXN levels as a novel surrogate endpoint to support an accelerated approval pathway, with a rolling BLA submission scheduled to begin in June 2026. Clinical data from the open-label study demonstrates remarkable efficacy, with 100% of evaluated patients achieving skin FXN levels above 50% of healthy controls at 6 months, alongside a median mFARS improvement of -2.20 points (compared to a +1.00 point decline in natural history cohorts). Supported by a robust balance sheet of $200.4 million in cash and investments—providing a runway into Q2 2027—Larimar represents a compelling investment opportunity ahead of major near-term regulatory and clinical catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$14.40

High · most bullish analyst$26.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.0015%

The FDA raises objections during the rolling BLA review regarding the safety database, citing the historical 7 cases of anaphylaxis out of 39 open-label participants, or rejects skin FXN as a reasonably likely surrogate endpoint, demanding full Phase 3 clinical data prior to approval. This delays potential approval and launch to 2029 or later, forcing Larimar to execute highly dilutive capital raises as its cash runway runs out in mid-2027. Additionally, competitive pressures or safety-related discontinuations in the Phase 3 trial severely limit the commercial viability of nomlabofusp.

Base CaseCentral scenario

$15.2960%

Larimar successfully initiates its rolling BLA in June 2026 and completes the submission with CMC modules in 2H 2026. The global Phase 3 confirmatory trial begins dosing in mid-2026 as planned. The FDA accepts skin FXN as a surrogate endpoint and grants accelerated approval in H1 2027, with a commercial launch shortly thereafter. The modified dosing and premedication regimen successfully mitigates severe allergic reactions, keeping the rate of new anaphylaxis events minimal. Nomlabofusp establishes itself as the standard of care for FA, capturing a significant share of the estimated 5,000 U.S. and 20,000 global patient populations.

Bull CaseUpside scenario

$26.0025%

The FDA grants accelerated approval to nomlabofusp in early 2027 based on skin FXN surrogate endpoint data, leading to a highly successful U.S. launch in H1 2027. The drug achieves rapid market penetration, capturing over 30% of the U.S. FA market by 2029 due to its disease-modifying profile. The global Phase 3 confirmatory trial meets its primary endpoint (mFARS Upright Stability Score) with an excellent safety profile, completely resolving historical anaphylaxis concerns through the new premedication protocol. Larimar successfully expands its intracellular delivery platform to target other rare mitochondrial and orphan diseases, driving substantial long-term valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class disease-modifying mechanism of action targeting the root cause of Friedreich's ataxia (FXN deficiency) rather than just managing symptoms.
Strong regulatory tailwinds, including FDA Breakthrough Therapy Designation, START pilot program participation, and alignment on skin FXN as a surrogate endpoint for accelerated approval.
Compelling clinical efficacy showing 100% of evaluated patients achieved skin FXN levels above 50% of healthy controls at 6 months, with directional improvements across mFARS, FARS-ADL, 9-HPT, and MFIS.
Robust financial position with $200.4 million in cash and investments as of March 31, 2026, extending the operational runway into Q2 2027 and covering key registrational milestones.

Key Investment Risks

Binary regulatory risk associated with the FDA's final acceptance of the rolling BLA and the surrogate endpoint framework for accelerated approval.
Clinical safety risks, specifically the historical incidence of anaphylaxis (7 out of 39 open-label participants), which requires strict adherence to a modified dosing and premedication protocol.
Execution and enrollment risks associated with the global confirmatory Phase 3 trial across multiple international jurisdictions.
Long-term funding risk if commercialization is delayed, as clinical-stage biotechs require substantial capital to scale commercial operations.

Thesis Invalidation Triggers

FDA refusal to file or complete the review of the rolling BLA, or a formal rejection of skin FXN as a surrogate endpoint for accelerated approval.
A cluster of new, severe anaphylaxis or serious adverse safety events in the open-label study or Phase 3 trial despite the modified dosing and premedication protocol.
Failure to initiate or significantly delay the global confirmatory Phase 3 trial dosing beyond 2026.
A material downward revision of the projected cash runway due to unexpected clinical trial or manufacturing scale-up costs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.